Fig. 5.

Stoichiometry of deacetylase- and CBP/p300-regulated acetylation sites. a The category scatterplot shows the distributions of acetylation sites that are not regulated (NR), more than two-fold (>2×) upregulated, or more than four-fold (>4×) upregulated, by the indicated deacetylase inhibitors as determined by²¹. Class I KDAC inhibitors primarily target HDACs 1, 2, 3, and 8, and were determined by the median SILAC ratio of apicidin, MS-275, valproic acid, and sodium butyrate-treated HeLa cells. Tubacin is an HDAC6 inhibitor and nicotinamide inhibits Sirtuin deacetylases, but the regulated sites are mostly attributed to SIRT1²¹. b CBP/p300 regulates an increasing fraction of high stoichiometry acetylation sites. CBP/p300-regulated sites were determined by¹². c Acetylation sites that are most affected (>8× reduced) by loss of CBP/p300 activity have higher median stoichiometry than sites that are only modestly affected (2–4× reduced). Source data are provided as a Source Data file